Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Biotech Investor RA Capital Makes Strong Case for New SPAC (<em>The Deal</em>)

Biotech Investor RA Capital Makes Strong Case for New SPAC (The Deal)

Related Content

The Competition for AI’s Scarcest Resource

Antitrust and Competition Technology Year in Review 2025

The UK’s Ransomware Strategy: What the UK Government’s Response Signals

Regulators Consider a New Theory on Algorithmic Coordination

AI Risk Meets Cyber Governance:
NIST’s Draft Cyber AI Profile

Deadlines Approaching for Reporting 2025 ISO Exercises and ESPP Share Transfers

2026 HSR Thresholds Announced: $133.9 Million

Cybersecurity’s New Power Dynamics

Goodwin Advises Marshall Wace on Co-Leading Achieve Life Sciences’ $354 Million Private Placement

Global Capital Markets & the U.S. Securities Laws 2026

Goodwin Advises Ralio on Raising $2.5 Million in Pre-Seed Round

Goodwin Advises Cocoon on $15 Million Series A

Goodwin Boosts Tech Group With Return of Russell (The Deal)

Factors Driving Change For Medtechs And Biotechs – A Legal View (In Vivo)

Goodwin Expands Technology Group With Addition of Veteran M&A Partner Michael Russell in San Francisco

M&A Co-Head Rejoins Goodwin in SF (Law360)

Technology

Private Equity

Life Sciences

Capital Markets

Mergers & Acquisitions

Special Purpose Acquisition Companies (SPACs)

Technology M&A